Equities

Bioventix PLC

BVXP:LSE

Bioventix PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)4,450.00
  • Today's Change0.00 / 0.00%
  • Shares traded1.41k
  • 1 Year change16.95%
  • Beta0.3038
Data delayed at least 20 minutes, as of Apr 29 2024 16:19 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Bioventix PLC grew revenues 9.36% from 11.72m to 12.82m while net income improved 9.10% from 7.67m to 8.37m.
Gross margin93.75%
Net profit margin63.73%
Operating margin78.69%
Return on assets69.72%
Return on equity79.14%
Return on investment79.03%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at Bioventix PLC fell by 410.83k. However, the company earned 7.80m from its operations for a Cash Flow Margin of 60.88%. In addition the company generated 90.51k cash from investing, though they paid out 8.30m more in financing than they received.
Cash flow per share1.66
Price/Cash flow per share26.43
Book value per share2.19
Tangible book value per share2.19
More ▼

Balance sheet in GBPView more

Bioventix PLC has little financial risk as the capital structure does not rely on leverage.
Current ratio7.04
Quick ratio6.69
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in GBP

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 20.63% and 8.48%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg)3.06%
Div growth rate (5 year)20.03%
Payout ratio (TTM)95.17%
EPS growth(5 years)7.88
EPS (TTM) vs
TTM 1 year ago		2.02
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.